A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 689
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : Ad5
Long Form : adenovirus type 5
No. Year Title Co-occurring Abbreviation
2020 A tropism-transformed Oncolytic Adenovirus with Dual Capsid Modifications for enhanced Glioblastoma Therapy. CAR, pIX, TRAIL
2020 Adenovirus targets transcriptional and posttranslational mechanisms to limit gap junction function. ---
2020 Adenovirus-Antibody Complexes Contributed to Lethal Systemic Inflammation in a Gene Therapy Trial. DCs, Ig
2020 Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy. GFP
2020 Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity. Ad35, NAbs
2020 Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. MPER
2020 Expanding the Spectrum of Adenoviral Vectors for Cancer Therapy. ADVs, OAs, OVs
2020 Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. GMTs, RBD, SARS-CoV-2
2020 Recombinant Human Adenovirus Type 5 Co-expressing RABV G and SFTSV Gn Induces Protective Immunity Against Rabies Virus and Severe Fever With Thrombocytopenia Syndrome Virus in Mice. DCs, LNs, RABV, SFTS, SFTSV
10  2020 Rectal Acquisition of SIVmac239 Infection Despite Vaccine-Induced Immune Responses Against the Entire SIV Proteome. Env, HIV, MVA, NAbs, RMs, RRV, SIV, VSV
11  2020 Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. SARS-CoV-2
12  2020 Suspension culture of Vero cells for the production of adenovirus type 5. ---
13  2020 Targeting Antigen to the Surface of EVs Improves the InVivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice. Ad, EGFP, EVs
14  2020 The Atoh1 expression levels are correlated with the arrangement, ciliary morphology, and electrophysiological characteristics of ectopic hair cell-like cells. EHCLCs, LER
15  2019 A novel oncolytic adenovirus inhibits hepatocellular carcinoma growth. E1A, GP73, HCC, HE, MTT, OA, qRT-PCR, SphK1, TEM
16  2019 A rapid strategy for constructing novel simian adenovirus vectors with high viral titer and expressing highly antigenic proteins applicable for vaccine development. ORF6, SAdV23, ZIKV
17  2019 Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques. AE, BAL, IM, Mtb, NHP, TB
18  2019 Duration of protection and humoral immunity induced by an adenovirus-vectored subunit vaccine for foot-and-mouth disease (FMD) in Holstein steers. ASCs, FMD, FMDV
19  2019 Rodents Versus Pig Model for Assessing the Performance of Serotype Chimeric Ad5/3 Oncolytic Adenoviruses. Ad, Ad3
20  2019 Skin immunisation activates an innate lymphoid cell-monocyte axis regulating CD8+ effector recruitment to mucosal tissues. FRT
21  2019 Viral vector and route of administration determine the ILC and DC profiles responsible for downstream vaccine-specific immune outcomes. cDC, DC, i.n, ILC, IM, pDC, rFPV, rMVA, RV
22  2018 Adenovirus Vector Vaccination Impacts NK Cell Rheostat Function following Lymphocytic Choriomeningitis Virus Infection. LCMV, NK
23  2018 Blood Coagulation Factor X Exerts Differential Effects on Adenovirus Entry into Human Lymphocytes. FX, HSPGs, NK, PBL
24  2018 Hexons from adenovirus serotypes 5 and 48 differentially protect adenovirus vectors from neutralization by mouse and human serum. FX
25  2018 Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer. HVRs
26  2018 Scavenger receptor-mediated Ad5 entry and acLDL accumulation in monocytes/macrophages synergistically trigger innate responses against viral infection. AcLDL, SR-A
27  2018 Serotype-specific restriction of wild-type adenoviruses by the cellular Mre11-Rad50-Nbs1 complex. DDR, MRN
28  2018 Therapeutic Efficacy of Vectored PGT121 Gene Delivery in HIV-1-Infected Humanized Mice. AAV1, BLT, bNAbs
29  2018 Tridimensional infiltration of DNA viruses into the host genome shows preferential contact with active chromatin. CGIs, CHi-C, HBV, HEG, TSSs
30  2017 A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression. CAR, CRAds
31  2017 Adenovirus Serotype 5 Vaccination Results in Suboptimal CD4 T Helper 1 Responses in Mice. GP, IL-2, LCMV, Tfh, Th1
32  2017 Afferent synaptogenesis between ectopic hair-cell-like cells and neurites of spiral ganglion induced by Atoh1 in mammals in vitro. Atoh1, CtBP2, EHCLCs, GluR2, HCs, LER, PSD, SGNs
33  2017 Biodistribution and residence time of adenovector serotype 5 in normal and immunodeficient mice and rats detected with bioluminescent imaging. Ad5-Fluc
34  2017 Cell-Surface Integrins and CAR Are Both Essential for Adenovirus Type 5 Transduction of Canine Cells of Lymphocytic Origin. CAR, q-RT-PCR
35  2017 Comparison of Liver Detargeting Strategies for Systemic Therapy with Oncolytic Adenovirus Serotype 5. PEG
36  2017 Decreased Vector Gene Expression from E2b Gene-Deleted Adenovirus Serotype 5 Vaccines Intensifies Proinflammatory Immune Responses. hPBMCs
37  2017 Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer. EnAd
38  2017 Immune efficacy of an adenoviral vector-based swine influenza vaccine against antigenically distinct H1N1 strains in mice. ---
39  2017 New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission. TBV
40  2017 Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia. VSV
41  2016 A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors. Ad48, ASP-2, pIX
42  2016 Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy. Ad, HVR1, pIX
43  2016 Adenovirus coxsackie adenovirus receptor-mediated binding to human erythrocytes does not preclude systemic transduction. CAR
44  2016 Adenovirus serotype 5 vaccine vectors trigger IL-27-dependent inhibitory CD4+ T cell responses that impair CD8+ T cell function. ---
45  2016 Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition. ---
46  2016 An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates. EBOV, GP, MakGP, NHPs
47  2016 Development of an Ad5H3 Chimera Using the "Antigen Capsid-Incorporation" Strategy for an Alternative Vaccination Approach. Ad3, hexon5, HVR2, PEI
48  2016 Enhanced immune responses against Japanese encephalitis virus using recombinant adenoviruses coexpressing Japanese encephalitis virus envelope and porcine interleukin-6 proteins in mice. ELISA, IL-6, JEV
49  2016 HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response. ---
50  2016 Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions. Ad, Ad41, NAb
51  2016 RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian Cancer. HGSOC, HR
52  2016 Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity. FX
53  2016 Suppression of Immune Response to Adenovirus Serotype 5 Vector by Immunization with Peptides Containing an MHC Class II Epitope and a Thio-Oxidoreductase Motif. NKT
54  2016 The relevance of coagulation factor X protection of adenoviruses in human sera. FX
55  2016 [Detection of neutralizing antibody to human adenovirus type 5 in marmosets]. ---
56  2015 Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates. EBOV
57  2015 Biobased monoliths for adenovirus purification. ---
58  2015 Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach. HR-HPV, HVRs, VLP
59  2015 Evaluation of a Fiber-Modified Adenovirus Vector Vaccine against Foot-and-Mouth Disease in Cattle. Ad5.A24, APC, FMD, FMDV
60  2015 Impact of natural IgM concentration on gene therapy with adenovirus type 5 vectors. ---
61  2015 Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo. FX, HVR
62  2015 Mucosal vaccination by adenoviruses displaying reovirus sigma 1. ---
63  2015 Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study. AAV-po6, EBOV
64  2015 Protective Efficacy in Sheep of Adenovirus-Vectored Vaccines against Bluetongue Virus Is Associated with Specific T Cell Responses. BTV
65  2015 Robust design of adenovirus purification by two-column, simulated moving-bed, size-exclusion chromatography. SEC
66  2015 Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. MERS-CoV
67  2015 The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. CEA, TAAs
68  2015 Transcriptome sequencing and development of an expression microarray platform for liver infection in adenovirus type 5-infected Syrian golden hamsters. ---
69  2015 Utilizing the antigen capsid-incorporation strategy for the development of adenovirus serotype 5-vectored vaccine approaches. HVR, PEI
70  2015 Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters. ---
71  2014 A fiber-modified adenovirus co-expressing HSV-TK and Coli.NTR enhances antitumor activities in breast cancer cells. CAR, Coli.NTR, HSV-TK
72  2014 Adenoviral targeting using genetically incorporated camelid single variable domains. hCEA, VHH
73  2014 Adenovirus E1B 19-kilodalton protein modulates innate immunity through apoptotic mimicry. E1B 19K
74  2014 Adenovirus purification by two-column, size-exclusion, simulated countercurrent chromatography. HCP, SEC
75  2014 Atoh1 expression levels define the fate of rat cochlear nonsensory epithelial cells invitro. Atoh1, EHCLCs, LER
76  2014 CD46-mediated transduction of a species D adenovirus vaccine improves mucosal vaccine efficacy. ---
77  2014 Development of dual-activity vectors by co-envelopment of adenovirus and SiRNA in artificial lipid bilayers. ---
78  2014 Establishment of a mouse melanoma model system for the efficient infection and replication of human adenovirus type 5-based oncolytic virus. CAR
79  2014 Evaluation of novel large cut-off ultrafiltration membranes for adenovirus serotype 5 (Ad5) concentration. PES, RC, UF
80  2014 Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy. ---
81  2014 Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors. HVRs, PD-1
82  2014 Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-gamma secretion with increased HIV-1 infection risk: a cohort-based modeling study. HRs, IFN-gamma, PBMC
83  2014 Increased adenovirus Type 5 mediated transgene expression due to RhoB down-regulation. ---
84  2014 Interaction of adenovirus type 5 E4orf4 with the nuclear pore subunit Nup205 is required for proper viral gene expression. ARM, NPC, NPCs, PP2A
85  2014 Neural stem cell-derived exosomes mediate viral entry. CAR, TIM-4
86  2014 Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses. Ad35, CAR
87  2014 Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses. AOR, BMI, HSV-2, MRK
88  2014 Priming of CD8 T cells by adenoviral vectors is critically dependent on B7 and dendritic cells but only partially dependent on CD28 ligation on CD8 T cells. ---
89  2014 Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. ---
90  2014 Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation. ---
91  2014 STAT1 interaction with E3-14.7K in monocytes affects the efficacy of oncolytic adenovirus. ---
92  2014 Stimulation of innate immunity by in vivo cyclic di-GMP synthesis using adenovirus. DGC
93  2014 The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus. HCMV, HPV-16, IFITM
94  2014 The influence of delivery vectors on HIV vaccine efficacy. ---
95  2014 The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting. ECs, MBP
96  2014 The targeted transduction of MMP-overexpressing tumor cells by ACPP-HPMA copolymer-coated adenovirus conjugates. ACPP, CPPs, MMP
97  2014 Two replication-defective adenoviral vaccine vectors for the induction of immune responses to PPRV. ---
98  2014 Type III interferon protects swine against foot-and-mouth disease. FMD, IFN, poIFN-lamda3
99  2014 Vaccination with recombinant adenoviruses expressing the peste des petits ruminants virus F or H proteins overcomes viral immunosuppression and induces protective immunity against PPRV challenge in sheep. ---
100  2013 A myeloid cell-binding adenovirus efficiently targets gene transfer to the lung and escapes liver tropism. KC